| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |